"Non-alcoholic Fatty Liver Disease/drug therapy"[MAJR] - Search Results

Year	Number of Results
2013	12
2014	122
2015	182
2016	208
2017	237
2018	290
2019	362
2020	486
2021	549
2022	606
2023	634
2024	219

1

Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD).

Rong L, Zou J, Ran W, Qi X, Chen Y, Cui H, Guo J. Rong L, et al. Front Endocrinol (Lausanne). 2023 Jan 16;13:1087260. doi: 10.3389/fendo.2022.1087260. eCollection 2022. Front Endocrinol (Lausanne). 2023. PMID: 36726464 Free PMC article. Review.

2

Naringenin attenuates non-alcoholic fatty liver disease by down-regulating the NLRP3/NF-κB pathway in mice.

Wang Q, Ou Y, Hu G, Wen C, Yue S, Chen C, Xu L, Xie J, Dai H, Xiao H, Zhang Y, Qi R. Wang Q, et al. Br J Pharmacol. 2020 Apr;177(8):1806-1821. doi: 10.1111/bph.14938. Epub 2020 Jan 30. Br J Pharmacol. 2020. PMID: 31758699 Free PMC article.

3

Hyperoside attenuates non-alcoholic fatty liver disease in rats via cholesterol metabolism and bile acid metabolism.

Wang S, Sheng F, Zou L, Xiao J, Li P. Wang S, et al. J Adv Res. 2021 Jun 8;34:109-122. doi: 10.1016/j.jare.2021.06.001. eCollection 2021 Dec. J Adv Res. 2021. PMID: 35024184 Free PMC article.

4

Nonalcoholic fatty liver disease: another leap forward.

Abdelmalek MF. Abdelmalek MF. Nat Rev Gastroenterol Hepatol. 2021 Feb;18(2):85-86. doi: 10.1038/s41575-020-00406-0. Nat Rev Gastroenterol Hepatol. 2021. PMID: 33420415 Free PMC article. Review.

5

Mouse models of nonalcoholic fatty liver disease (NAFLD): pathomechanisms and pharmacotherapies.

Fang T, Wang H, Pan X, Little PJ, Xu S, Weng J. Fang T, et al. Int J Biol Sci. 2022 Sep 6;18(15):5681-5697. doi: 10.7150/ijbs.65044. eCollection 2022. Int J Biol Sci. 2022. PMID: 36263163 Free PMC article. Review.

6

Cyanidin-3-O-glucoside improves non-alcoholic fatty liver disease by promoting PINK1-mediated mitophagy in mice.

Li X, Shi Z, Zhu Y, Shen T, Wang H, Shui G, Loor JJ, Fang Z, Chen M, Wang X, Peng Z, Song Y, Wang Z, Du X, Liu G. Li X, et al. Br J Pharmacol. 2020 Aug;177(15):3591-3607. doi: 10.1111/bph.15083. Epub 2020 Jun 14. Br J Pharmacol. 2020. PMID: 32343398 Free PMC article.

7

Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease.

Fraile JM, Palliyil S, Barelle C, Porter AJ, Kovaleva M. Fraile JM, et al. Drug Des Devel Ther. 2021 Sep 22;15:3997-4009. doi: 10.2147/DDDT.S315724. eCollection 2021. Drug Des Devel Ther. 2021. PMID: 34588764 Free PMC article. Review.

8

Therapeutic pipeline in nonalcoholic steatohepatitis.

Vuppalanchi R, Noureddin M, Alkhouri N, Sanyal AJ. Vuppalanchi R, et al. Nat Rev Gastroenterol Hepatol. 2021 Jun;18(6):373-392. doi: 10.1038/s41575-020-00408-y. Epub 2021 Feb 10. Nat Rev Gastroenterol Hepatol. 2021. PMID: 33568794 Review.

9

An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH.

Tacke F, Puengel T, Loomba R, Friedman SL. Tacke F, et al. J Hepatol. 2023 Aug;79(2):552-566. doi: 10.1016/j.jhep.2023.03.038. Epub 2023 Apr 14. J Hepatol. 2023. PMID: 37061196 Review.

10

Hyodeoxycholic acid ameliorates nonalcoholic fatty liver disease by inhibiting RAN-mediated PPARα nucleus-cytoplasm shuttling.

Zhong J, He X, Gao X, Liu Q, Zhao Y, Hong Y, Zhu W, Yan J, Li Y, Li Y, Zheng N, Bao Y, Wang H, Ma J, Huang W, Liu Z, Lyu Y, Ke X, Jia W, Xie C, Hu Y, Sheng L, Li H. Zhong J, et al. Nat Commun. 2023 Sep 6;14(1):5451. doi: 10.1038/s41467-023-41061-8. Nat Commun. 2023. PMID: 37673856 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

3,391 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

3,391 results

Results by year